OHSU
Return to Listing

5 result(s) for Other Hematologic Malignancy

PI Name Protocol # Title
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Emma Scott IRB00009421 A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Richard Maziarz IRB00009585 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Morgan Hakki IRB00009894 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Kim-Hien Dao IRB00010262 Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program